CDXS · Codexis, Inc.
$1.45
+0.02 (+1.40%)
At close · Aug 5
Market Cap
$131.35M
Shares
90.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.45
Open$1.43
Day$1.41–1.47
52W$0.96–3.87
Avg vol 30d1.3M
Short int3.7M · 4.1% float · 5.0d
Short vol48%
Last earningsJul 23, 2026
DataJan 2020–Aug 2026
Filing10-Q · May 7
Up next
Next earnings call
Oct 12, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−36%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−44%
trailing
6-month return
+22%
trailing
YTD return
−11%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
33 of 133 funds reported for Jun 30 · net -2.2M sh shares · +3 new
Insider flow
Distributing
Net -$6.2K over 90 days · 100% sells
Short interest
Rising
4.12% of float · ▲ +16.0% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
EPS growth
+44%
Y/Y
Free cash flow
$-23.8M
Balance sheet
$10.7M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Cash, cash equivalents and short-term investments
· as of June 30, 2026
Initiated
at least $54.9M
Guided vs delivered
· last 1 settled
Revenue
2025
guided $64M – $68M
$70.39M
Beat +6.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−36%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
33 of 133 funds reported for Jun 30 · net -2.2M sh shares · +3 new
Insider flow
Distributing
Net -$6.2K over 90 days · 100% sells
Short interest
Rising
4.12% of float · ▲ +16.0% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 17%
52-wk high $4
vs 200-day avg -26%
vs 50-day avg -36%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Product gross margin | 71% | first quarter of 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CDXS
this stock
Codexis, Inc.
|
$131.35M | -11.0% | +32.3% | — | 4.1% |
|
ONC
BeOne Medicines Ltd.
|
$453.48B | +7.8% | +22179.2% | 697.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.47B | +6.9% | +46.2% | 27.5 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.17B | -0.2% | +20.8% | 18.8 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CDXS | -1.4% | -44.2% | +21.9% | +3.6% | -11.0% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -6.9% | -47.5% | +10.6% | +0.5% | -23.9% |
Key facts
CIK
1200375
CUSIP
192005106
13F (30d)
33 filings
32 filers
Visit website
Investor relations